| Author (Corporate) | European Court of Auditors |
|---|---|
| Publisher | Publications Office of the European Union |
| Series Title | ECA Special Reports |
| Series Details | 19/2022, Number 19 |
| Publication Date | September 2022 |
| ISBN | 978-92-847-8426-4 I |
| ISSN | 1977-5679 |
| EC | QJ-AB-22-017-EN-N |
| Content Type | News, Report |
Summary:The European Union (EU) launched its vaccine procurement strategy in June 2020. By the end of 2021, it had signed €71 billion worth of contracts securing up to 4.6 billion doses. The European Court of Auditors (ECA) concludes that the EU secured a diversified vaccine portfolio for Member States, though it started procurement later than the United Kingdom (UK) and the United States (US). The contracts signed in 2021 have stronger provisions on key issues than those signed in 2020. The Court found that the European Commission had limited leverage to overcome supply challenges and the size of its impact on the ramp-up of vaccine production was unclear. The recommendations focus on the need to draw lessons learnt and run exercises to test the EU’s updated pandemic preparedness framework. |
|
| Source Link |
Link to Main Source
https://www.doi.org/10.2865/569767
Alternative sources
|
| Related Links |
|
| Subject Categories | Health |
| Subject Tags | Medicines | Medical Devices, Risk | Crisis Management |
| Keywords | COVID-19 (Coronavirus), Public Procurement |
| International Organisations | European Union [EU] |
